Contact

Press Release

Press Release
Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine
SAN DIEGO, CA / ACCESSWIRE / September 18, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA
SAN DIEGO, CA / ACCESSWIRE / August 29, 2019 / Calidi Biotherapeutics Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer announced today, the completion…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board
Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of a distinguished innovator in the field of cancer diagnosis…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field
SAN DIEGO, CA / ACCESSWIRE / July 10, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of stem cell-based delivery of oncolytic virus-based immunotherapies for cancer,…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board
SAN DIEGO (PRWEB) JUNE 03, 2019 – Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of Dr. Dmitriy…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board
SAN DIEGO, May 30, 2019 /PRNewswire/ — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells
SAN DIEGO, May 28, 2019 /PRNewswire/ — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced their ongoing scientific collaboration with…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa
SAN DIEGO (PRWEB) APRIL 15, 2019 Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that Allan Camaisa, Calidi Biotherapeutics CEO,…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Launches Scientific and Medical Advisory Board
SAN DIEGO, Jan. 3, 2019 /PRNewswire-PRWeb/ — Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding of a scientific…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO
SAN DIEGO, May 24, 2018 — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced a focused effort to advance its…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
SAN DIEGO, Nov. 6, 2018  — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from…
 
Read Morelaunch
Press Release
Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses
SAN DIEGO, October 25, 2018 – Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a…
 
Read Morelaunch